Display options
Cite
Sun L, Pang Y, Wang X, et al. Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters. Acta Pharm Sin B. 2019;9(4):702-710doi: 10.1016/j.apsb.2019.02.004.
Sun, L., Pang, Y., Wang, X., Wu, Q., Liu, H., Liu, B., Liu, G., Ye, M., Kong, W., & Jiang, C. (2019). Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters. Acta pharmaceutica Sinica. B, 9(4), 702-710. https://doi.org/10.1016/j.apsb.2019.02.004
Sun, Lulu, et al. "Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters." Acta pharmaceutica Sinica. B vol. 9,4 (2019): 702-710. doi: https://doi.org/10.1016/j.apsb.2019.02.004
Sun L, Pang Y, Wang X, Wu Q, Liu H, Liu B, Liu G, Ye M, Kong W, Jiang C. Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters. Acta Pharm Sin B. 2019 Jul;9(4):702-710. doi: 10.1016/j.apsb.2019.02.004. Epub 2019 Feb 16. PMID: 31384531; PMCID: PMC6664038.
Copy Download .nbib Format: NLM
Share it on

Acta Pharm Sin B. 2019 Jul;9(4):702-710. doi: 10.1016/j.apsb.2019.02.004. Epub 2019 Feb 16.

Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters.

Acta pharmaceutica Sinica. B

Lulu Sun, Yuanyuan Pang, Xuemei Wang, Qing Wu, Huiying Liu, Bo Liu, George Liu, Min Ye, Wei Kong, Changtao Jiang

Affiliations

  1. Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, and the Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing 100191, China.
  2. Institute of Cardiovascular Sciences and Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Peking University, Beijing 100191, China.
  3. State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.

PMID: 31384531 PMCID: PMC6664038 DOI: 10.1016/j.apsb.2019.02.004

Abstract

Since metabolic process differs between humans and mice, studies were performed in hamsters, which are generally considered to be a more appropriate animal model for studies of obesity-related metabolic disorders. The modulation of gut microbiota, bile acids and the farnesoid X receptor (FXR) axis is correlated with obesity-induced insulin resistance and hepatic steatosis in mice. However, the interactions among the gut microbiota, bile acids and FXR in metabolic disorders remained largely unexplored in hamsters. In the current study, hamsters fed a 60% high-fat diet (HFD) were administered vehicle or an antibiotic cocktail by gavage twice a week for four weeks. Antibiotic treatment alleviated HFD-induced glucose intolerance, hepatic steatosis and inflammation accompanied with decreased hepatic lipogenesis and elevated thermogenesis in subcutaneous white adipose tissue (sWAT). In the livers of antibiotic-treated hamsters, cytochrome P450 family 7 subfamily B member 1 (CYP7B1) in the alternative bile acid synthesis pathway was upregulated, contributing to a more hydrophilic bile acid profile with increased tauro-

Keywords: ALT, alanine amino-transferase; AST, aspartate transaminase; AUC, area under curve; ApoB, apolipoprotein B; BAs, bile acids; BSH, bile acid hydrolase; CA, cholic acid; CAPE, caffeic acid phenethyl ester; CDCA, chenodeoxycholic acid; CETP, cholesterol ester transfer protein; CYP27A1, cytochrome P450 family 27 subfamily A member 1; CYP7A1, cytochrome P450 family 7 subfamily A member 1; CYP7B1; CYP7B1, cytochrome P450 family 7 subfamily B member 1; CYP8B1, cytochrome P450 family 8 subfamily B member 1; DCA, deoxycholic acid; FGF15/19, fibroblast growth factor 15/19; FXR; FXR, farnesoid X receptor; GCA, glycocholic acid; GCDCA, glycochenodeoxycholic acid; GTT, glucose tolerance test; Gut microbiota; H&E, hematoxylin and eosin; HFD, high fat diet; ITT, insulin tolerance test; LCA, lithocholic acid; Metabolic disorders; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PBA/SBA, primary bile acids to secondary bile acids; T2D, type 2 diabetes; TC, total cholesterol; TCA, taurocholic acid; TG, triglycerides; TβMCA; TβMCA, tauro-β-muricholic acid; UDCA, ursodeoxycholic acid; UPLC–MS/MS, ultra performance liquid chromatography–tandem mass spectrometry; VLDL, very low-density lipoprotein; eWAT, epididymal white adipose tissue; sWAT, subcutaneous white adipose tissue

References

  1. Science. 1999 May 21;284(5418):1362-5 - PubMed
  2. Science. 1999 May 21;284(5418):1365-8 - PubMed
  3. J Biol Chem. 2002 Aug 30;277(35):31646-55 - PubMed
  4. Am J Physiol Gastrointest Liver Physiol. 2003 Sep;285(3):G494-502 - PubMed
  5. J Lipid Res. 2006 Feb;47(2):241-59 - PubMed
  6. Nature. 2006 Dec 14;444(7121):881-7 - PubMed
  7. Nature. 2006 Dec 21;444(7122):1027-31 - PubMed
  8. Nat Rev Drug Discov. 2008 Aug;7(8):678-93 - PubMed
  9. Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13580-5 - PubMed
  10. Physiol Rev. 2009 Jan;89(1):147-91 - PubMed
  11. Am J Physiol Endocrinol Metab. 2009 Aug;297(2):E462-73 - PubMed
  12. Biochem Biophys Res Commun. 2010 Aug 6;398(4):619-26 - PubMed
  13. Diabetes. 2010 Aug;59(8):1899-905 - PubMed
  14. J Nutr. 2012 Apr;142(4):704-9 - PubMed
  15. Mol Cell Endocrinol. 2013 Apr 10;368(1-2):17-29 - PubMed
  16. Cell Metab. 2013 Feb 5;17(2):225-35 - PubMed
  17. J Lipid Res. 2013 May;54(5):1241-54 - PubMed
  18. J Lipid Res. 2013 May;54(5):1283-99 - PubMed
  19. Diabetes. 2013 Dec;62(12):4184-91 - PubMed
  20. Nature. 2013 Aug 29;500(7464):541-6 - PubMed
  21. Nat Rev Gastroenterol Hepatol. 2014 Feb;11(2):79-80 - PubMed
  22. Cell Rep. 2014 Apr 10;7(1):12-8 - PubMed
  23. Proc Natl Acad Sci U S A. 2014 May 20;111(20):7421-6 - PubMed
  24. Gut. 2015 Jun;64(6):872-83 - PubMed
  25. J Clin Invest. 2015 Jan;125(1):386-402 - PubMed
  26. J Hepatol. 2015 Jun;62(6):1234-6 - PubMed
  27. J Clin Endocrinol Metab. 2015 Sep;100(9):E1225-33 - PubMed
  28. Cell Metab. 2015 Sep 1;22(3):516-530 - PubMed
  29. Sci Rep. 2015 Sep 23;5:14405 - PubMed
  30. Cell Metab. 2015 Dec 1;22(6):971-82 - PubMed
  31. Nature. 2015 Dec 10;528(7581):262-266 - PubMed
  32. Cell. 2015 Dec 3;163(6):1360-74 - PubMed
  33. Nat Commun. 2015 Dec 15;6:10166 - PubMed
  34. J Lipid Res. 2016 Jul;57(7):1144-54 - PubMed
  35. Nat Rev Gastroenterol Hepatol. 2016 Jul;13(7):412-25 - PubMed
  36. Cell Metab. 2016 Jul 12;24(1):41-50 - PubMed
  37. Nat Rev Gastroenterol Hepatol. 2016 Sep;13(9):508-16 - PubMed
  38. Nature. 2016 Jul 06;535(7610):56-64 - PubMed
  39. J Lipid Res. 1989 May;30(5):719-30 - PubMed
  40. J Lipid Res. 2016 Dec;57(12):2130-2137 - PubMed
  41. Gastroenterology. 2016 Nov;151(5):845-859 - PubMed
  42. Acta Pharm Sin B. 2016 Sep;6(5):409-412 - PubMed
  43. Acta Pharm Sin B. 2016 Sep;6(5):453-459 - PubMed
  44. Nat Med. 2016 Oct 06;22(10):1079-1089 - PubMed
  45. Diabetes. 2017 Mar;66(3):613-626 - PubMed
  46. Acta Pharm Sin B. 2017 Mar;7(2):241-248 - PubMed
  47. Nat Med. 2017 Jul;23(7):850-858 - PubMed
  48. Nat Med. 2017 Jul;23(7):839-849 - PubMed
  49. Acta Pharm Sin B. 2017 Jul;7(4):453-460 - PubMed
  50. Acta Pharm Sin B. 2017 Jul;7(4):461-469 - PubMed
  51. Gut. 2018 Oct;67(10):1881-1891 - PubMed
  52. Gastroenterology. 2017 Nov;153(5):1320-1337.e16 - PubMed
  53. Nat Commun. 2017 Nov 27;8(1):1785 - PubMed
  54. Acta Pharm Sin B. 2018 Mar;8(2):178-187 - PubMed
  55. Nat Med. 2018 Dec;24(12):1919-1929 - PubMed
  56. Acta Pharm Sin B. 2018 Oct;8(6):919-932 - PubMed
  57. Acta Pharm Sin B. 2019 Mar;9(2):220-236 - PubMed

Publication Types